Background: Two previous phase II trials of docetaxel as first line chemotherapy of advanced breast cancer have been conducted by the Clinical Screening Group of the EORTC. In these 2 studies, docetaxel 100 mg/m 2 and 75 mg/m 2 were administered without routine premedication and produced overall response rates of 68% and 52% respectively. Fluid retention was the most problematic adverse event in these 2 studies in which premedication was not routinely administered. This study investigated the efficacy and safety profile of docetaxel with a 1-day prophylactic premedication.
Background: Two previous phase II trials of docetaxel as first line chemotherapy of advanced breast cancer have been conducted by the Clinical Screening Group of the EORTC. In these 2 studies, docetaxel 100 mg/m 2 and 75 mg/m 2 were administered without routine premedication and produced overall response rates of 68% and 52% respectively. Fluid retention was the most problematic adverse event in these 2 studies in which premedication was not routinely administered. This study investigated the efficacy and safety profile of docetaxel with a 1-day prophylactic premedication.
Patients and methods: Docetaxel 100 mg/m 2 was administered intravenously over 1 hour, every 3 weeks, to 37 women (aged 29-65 years) with advanced breast cancer. A 1-day regimen of intravenous antihistamine and oral corticosteroids was given with each dose. Full doses of docetaxel were administered in 179 of 200 cycles (89.5%), giving a median relative dose intensity of 0.98.
Results: Tumour regression was achieved in 25 patients (67.6%) after a median of 7 weeks, and 2 patients (5.4%) had a complete response. Response rates were 67.9% in patients with viscera] metastases, 76.9% in liver metastases and 83.3% in patients with > 2 organs involved. The median time to progression was 31 weeks (range 1-36+). After a median follow-up time of 6.9 months (range 4.6-9.4), 31 patients (83.7%) were still alive.
The most common adverse events (AE) were neutropenia (97%), alopecia (97%, grade 1-2), fluid retention (89%, mainly mild to moderate) and neurosensory disorders (81%, mainly mild to moderate). Only 5 patients experienced febrile neutropenia requiring hospitalisation and/or antibiotic therapy. Sixteen patients discontinued treatment because of fluid retention; nevertheless, 13 of these achieved an objective antitumour response and none had any significant deterioration in performance status. AEs were generally reversible and easily managed, and there were no deaths attributable to docetaxel-related AEs.
Conclusions: Docetaxel produces very effective tumour response with acceptable tolerability when used as first-line chemotherapy in patients with advanced breast cancer. The 1-day premedication regimen used in this study was less effective in reducing the incidence and severity or delaying
Introduction
Improved screening techniques and their increasingly widespread availability over the past few years have generally led to earlier detection and more successful treatment of primary breast tumours. Nevertheless, 40%-60% of women with breast cancer go on to develop advanced or metastatic disease, resulting in almost 60,000 deaths a year in Europe [1] . The natural course of metastatic breast cancer is highly variable, but the average survival time is 18 to 24 months. Established drug treatments do not markedly affect survival and are essentially palliative [2, 3] .
Up to a third of patients with advanced breast cancer respond to hormonal manipulation. However, for patients who do not respond, and for those who have hormone-independent or aggressive cancer types or who experience rapid progression, anticancer chemotherapy is required. Doxorubicin or its derivatives are currently the standard agents used in this situation, generally in combination with cyclophosphamide and 5-fluorouracil. Regimens containing these drugs have been shown to be the most effective in terms of response rate and time to progression [4] . However, doxorubicin produces cumulative cardiotoxicity, and the total dose administered must therefore be limited.
Recently, paclitaxel has been demonstrated to produce good results in breast cancer [5] [6] [7] . Paclitaxel promotes polymerisation of tubulin, increasing microtubule assembly and stabilising any microtubules already formed. This prevents the reorganisation of the microtubule network required to form the spindle during mitosis and, therefore, disrupts the distribution of chromosomes into daughter cells, preventing cell replication [5] . Docetaxel is another effective anticancer agent of the same chemical class as paclitaxel.
The anticancer activity of docetaxel has been demonstrated in several murine cancer screening models [8] . In in vitro comparisons with paclitaxel, docetaxel has been shown to be 2.5 to 5 times more active against various cancer cell lines [9] and to have equal or superior activity against a number of freshly explanted and cloned human cancer specimens, including breast cancers [10] .
Two previous phase II trials of docetaxel as first-line chemotherapy in patients with metastatic or locally advanced breast cancer have been conducted by the European Organization for Research and Treatment of Cancer (EORTC) Clinical Screening Group [11, 12] . In these 2 studies, docetaxel 100 mg/m 2 [11] and 75 mg/ m 2 [12] were administered without routine premedication, and produced overall response rates of 67.7% and 51.6%, respectively, in evaiuable patients. The safety profile of docetaxel was acceptable and the majority of acute and chronic adverse events were easy to manage. Fluid retention, which was a cumulative toxicity, was the most problematic adverse event in these 2 studies in which premedication was not routinely administered, being responsible for 50% and 41% of treatment discontinuations, respectively. A prophylactic regimen containing corticosteroids and antihistamines may be useful in delaying the onset and/or reducing the severity of fluid retention and/or reducing the incidence of treatment withdrawal resulting from this adverse effect.
This study investigated the efficacy (in terms of objective response rate, time to response, duration of response and time to progression) and safety profile of docetaxel 100 mg/m 2 with a routine 1-day prophylactic regimen of corticosteroids and antihistamines in women with metastatic or locally advanced breast cancer who had received no previous anticancer chemotherapy for their advanced disease. It is important to note that since this study was conducted, a 5-day corticosteroid-based premedication regimen has been found to be effective for minimising fluid retention [13] . The results of the present study will be discussed in relation to this. Studies with a 3-day corticosteroid-based premedication are ongoing.
Patients and methods

Patients
Patients eligible for the study were women aged 18 to 65 years with histologically proven breast cancer, bidimensionally measurable metastases or locally-advanced breast cancer, disease progression, a life expectancy greater than 12 weeks and a WHO performance status category of 0-2. Patients included in the study had not received prior chemotherapy for advanced disease, although previous adjuvant chemotherapy was allowed as long as there had been an interval of > 12 months between the end of this treatment and the beginning of the study. Previous hormonal treatment, either for initial or advanced disease, was also allowed. If a response to this treatment had been obtained, a 6-week interval between treatments was required. Previous radiotherapy was allowed, providing this had been to a site not being used to evaluate the response to docetaxel, unless there had been subsequent disease progression.
Patients were excluded if they had had previous cancers of any kind; bone metastases as the only measurable lesion; brain or leptomeningeal metastases; symptomatic peripheral neuropathy; clinically significant cardiac disease; neurological or psychiatric disorders; active uncontrolled infection; pleural effusion greater than 11 in volume; abnormal haematologjcal profile; impaired hepatic function (transaminases >2x upper normal limit [UNL] or >3x UNL in patients with proven liver metastases, and/or bilirubin > 1.25X UNL); impaired renal function (serum creatinine > 120 umol/1); or concurrent treatment with any experimental drug, colony stimulating factor, anticancer agent or coru'costeroid.
Study design and procedures
The study was of an open-label, nonrandomised design, and was performed at six centres in France between August 1993 and May 1994. It was conducted in accordance with the Hong Kong Amendment of the Declaration of Helsinki. Patients provided written informed consent, and the protocol received Ethics Committee approval before commencement.
Following baseline investigations, patients received docetaxel (Taxotere*, Rhone-Poulenc Rorer, France) 100 mg/m 2 once every 3 weeks on an outpatient basis. The dose was diluted in 250 ml 5% dextrose or 0.9% sodium chloride and administered intravenously (i.v.) over 1 hour, using a peristaltic pump. The investigarional premedication regimen used consisted of oral prednisolone or prednisone (130 mg, 12 and 6 hours before docetaxel, i.v. diphenhydramine and i.v. ranitidine (both 50 mg, 30 min before docetaxel), and these were co-administered as prophylaxis against hypersensitivity, skin reactions and fluid retention. Symptomatic treatment for nausea and vomiting, pain and any allergic reaction, were given as necessary. Patients were closely observed over the first few minutes of each infusion in case of an acute reaction.
Treatment was to continue at the scheduled dosage (100 mg/m 2 every 3 weeks) until there was evidence of progression or 6 cycles had been completed. However, if an adverse event occurred, the dose could be reduced to 75 mg/m 2 at the next cycle, and subsequently to 55 mg/m 2 if necessary, and/or the next cycle could be delayed by up to 7 days. Patients showing no response after 3 cycles were withdrawn and received alternative treatment All eligible patients were evaluated for response which was classified objectively according to WHO criteria (complete response [CR], partial response [PR], no change or progressive disease). The occurrence of pleural effusion or ascites was defined as progressive disease if this was substantiated by positive cytology. The time to response, time to progression (dated from first docetaxel infusion), duration of response (dated from the first infusion for PRs and from the date of observation of freedom from disease for CRs) and duration of survival (dated from the first infusion) were also recorded. Patients were followed every 3 months from study completion until death to determine overall survival time.
The safety profile was evaluated by 3-weekly medical history, physical examination, vital sign assessment, WHO performance status category evaluation, ECG, chest X-ray and clinical chemistry determinations (alkaline phosphatase, LDH, bilirubin, AST, ALT, serum creatinine, sodium, potassium, magnesium, calcium, protein and albumin). In addition, haematological counts were performed biweekly, a neurological examination was performed before cycle 3.
Adverse events arising during each cycle were either spontaneously reported by the patient or observed by the investigator. Patients were followed closely for 1 month after their last dose of docetaxel to determine any late adverse events.
Statistical methods
The number of patients to be enrolled was planned using a modified two-stage Fleming design [14, 15] . If at least one response was observed in the first 14 patients, an additional 16 patients were to be recruited. Seven or more responses among 30 patients would be considered promising. This procedure tests the null hypotheses that the true tumour response rate is < 10% (i.e., docetaxel would be of no further interest in breast cancer) versus the alternative, that the true response rate is >30% (i.e., docetaxel is of considerable interest). With 30 patients, the power of the study at the 3% level of significance was 84.5%.
Continuous data were summarised as the median and range, and 95% confidence interval were calculated [16) . Kaplan-Meier estimations were performed for censored data.
The 'relative dose intensity' was used as a measure of compliance to docetaxel treatment This was defined as the ratio between the delivered dose intensity (actual dose received in mg/mVweek) and the planned dose intensity (planned dose in mg/mVweek, as per protocol). 
Efficacy
An objective response (CR or PR) to docetaxel was obtained in 25 patients (67.6%; 95% CI: 50.2-82.0) and
Results
Patient baseline characteristics
Thirty-seven women, median age 48 years (range 29-65 years) were recruited by 7 centres in France. Patient demographic data and tumour characteristics at baseline are summarised in Table 1 . The majority of patients (75.7%) had visceral involvement and 18 patients (48.6%) had more than 2 sites of metastatic disease. All patients were treated with docetaxel and all were eligible for evaluation of efficacy and safety. Previous treatment included surgery (35 patients, 94.6%), radiotherapy (33 patients, 89.2%), neo-adjuvant or adjuvant chemotherapy in 24 patients (64.9%) 21 of whom had received an anthracycline-containing regimen, and hormonal manipulation in 21 patients (56.8%) 7 of whom had received hormonal treatment for advanced disease.
Withdrawals
The end of the study was defined as the completion of 6 cycles of docetaxel therapy. Eighteen patients (48.6%) withdrew from the study earlier because of drug-related adverse events and 1 patient (2.7%) withdrew because of an unrelated adverse event. Six patients (16.2%) were withdrawn because of disease progression, 1 (2.7%) because of suspected but unconfirmed progression, and 3 patients (8.1%) died of progressive disease. Four patients (10.8%) ended treatment after the protocol-defined endpoint and 1 (2.7%) refused further treatment after 5 cycles. At the study follow-up cut-off date, 3 patients were still receiving docetaxel. 2 patients (5.4%) achieved a complete response. Eight patients (21.6%) showed no change and 4 (10.8%) had progressive disease. Importantly, high response rates were seen even in patients with the poorest prognostic factors. Evaluation of response by disease site showed that docetaxel had good activity at all sites except lung ( Table 2) . Patients with visceral involvement and those with 3 or more metastatic sites had particularly good responses (67.9% and 83.3%, respectively), and patients with liver metastases achieved an impressive response rate of 76.9%. Overall, the response to docetaxel occurred after a median of 7 weeks (range 1+ to 22+). After a median follow-up time of 6.9 months (range 4.6-9.4 months), 31 patients were still alive; the median survival time had not been reached. The median time to first response was 7 weeks (range 1H-22+) and the median duration of response had not been reached. The median time to progression was 31 weeks (range 1-36+) ( Figure 1) ; however, at the time of the analysis, 15 of the 25 responders had no disease progression and 3 patients were still receiving treatment. Figure 1 . Kaplan-Meier curve of progression-free survival in 37 advanced breast cancer patients treated with docetaxel 100 mg/m 2 as a 1-hour infusion once every 3 weeks.
Safety
Adverse events (AEs) reported during the study were categorised according to the NCI-CTC system. No toxic deaths occurred. The most commonly observed AEs were alopecia (36 patients, 97.3%), grade 3-4 neutropenia (36 patients, 97.0%), fluid retention (33 patients, 89%, mainly mild to moderate) and neurosensory disorders (30 patients, 81.1%, all NCI grade 1 or 2).
Neutropenia was generally short-lived, and grade 4 neutropenia lasted for more than 7 days on only 10 (6.8%) of 148 evaluable cycles. All patients had recovered between days 19 and 25 of the cycle. The median neutrophil nadir was 0.1 x lOVmm 3 (range 0-3.3 x lOVmm 3 ) and the mean time to the nadir was 9 days (range 6-14 days). Febrile neutropenia (grade 2 fever [>38 *C] concomitant with grade 4 neutropenia, requiring hospitalisation and/or antibiotic therapy) occurred in 5 (13.5%) patients (2.5% of cycles). No cumulative haematological suppression was observed. Grade 3 thrombocytopenia and grade 3 anaemia each occurred in only 2 patients.
Fluid retention was mainly mild to moderate in severity and included peripheral oedema, effusions and weight gain. Other AEs, which included asthenia, nail disorders, skin reactions, nausea, vomiting, diarrhoea and stomatitis, were generally mild to moderate (grades 1 or 2), reversible and easily managed. Despite the administration of corticosteroid and antihistamine prophylaxis, mild hypersensitivity reactions (grade 1) occurred in 6 patients (16.2%), mostly within the first few minutes of the first infusion. These were managed by temporary interruption of the infusion and/or administration of corticosteroids and antihistamines. All patients were subsequently able to continue docetaxel treatment. No cardiotoxicity was observed.
Eighteen patients (48.6%) withdrew because of AEs. One patient withdrew due to skin and neurotoxicity and another patient because of nail infection. In the other 16 patients, withdrawal was due to fluid retention, although this was mild to moderate in the majority of cases and patients were generally able to continue to receive additional cycles before being withdrawn from docetaxel treatment. Indeed, 14 of these 16 patients showed no deterioration in WHO performance status between study entry and treatment discontinuation. More importantly, 13 of the 16 patients achieved an objective response (12 PRs and 1 CR), indicating that fluid retention does not interfere with the antitumour efficacy of docetaxel. The median cumulative dose to onset of fluid retention was 301 mg/ m 2 (range 98-595 mg/m 2 ), and the median cumulative dose to treatment discontinuation due to fluid retention was 698 mg/m 2 (range 98-995 mg/m 2 ).
Alkaline phosphatase and liver enzymes were analysed with reference to the presence of bone and/or liver metastases. No consistent or severe increases were determined in these or in any other serum chemistry parameter.
Fourteen patients (37.8%) experienced adverse events requiring hospitalisation, in 12 of whom (32.4%) it was considered related to the study drug.
Discussion
The aim of this open-label study was to assess the objective tumour response of docetaxel as first-line chemotherapy for advanced breast cancer and to investigate the effect of a routine 1-day prophylactic regimen on the safety profile of this agent. The overall response rate of 67.6% with a 95% CI of 50.2%-82.0% indicates that docetaxel has considerable activity in this group of patients with metastatic or locally advanced disease. Although randomised comparative clinical trials of docetaxel versus other agents have not yet been performed, the results achieved in the present study compare well with previously reported response rates of 25% to 53% with the most active and commonly-used mono therapies (e.g., doxorubicin, cyclophosphamide, 5-fluorouracil, methotrexate and mitomycin) in previously untreated metastatic disease [17] , and 50 to 82% for anthracycline-containing combination regimens [18] [19] [20] [21] [22] [23] [24] . They also compare favourably with the response rates of 61.5% and 56% achieved with paclitaxel 250 mg/m 2 in early studies, in which it was administered over 24 hours, with [7] and without [6] concomitant colony stimulating factors. More importantly, the response rate achieved with docetaxel in the present study appears to be superior to preliminary results of a study of first-line paclitaxel 250 mg/m 2 administered in the now accepted regimen of one 3-hour infusion every 3 weeks (4 PR in 17 patients; 23.5%) [25] . However, in the absence of a randomised, comparative trial of docetaxel and paclitaxel, no definite conclusion can presently be drawn concerning the relative efficacy of the 2 taxoids.
The response to docetaxel in the present study was notable in patients with visceral metastases, particularly those with liver involvement (77%). These patients have previously been considered to have a very poor prognosis [2, 3] . Furthermore, the response rate was not influenced by the number of organs involved; indeed, patients with involvement of 3 or more organs had a particularly good response (83%).
Response occurred in most patients during the first 3 cycles of docetaxel treatment The median time to progression was 31 weeks (range 1-36+). This compares well with most previous reports for standard chemotherapy regimens [18] [19] [20] [21] [22] [23] [24] . The median duration of response and median overall survival were not reached, since some patients were still responding and 31 patients were still alive at the cut-off date of the analysis.
The majority of patients were able to tolerate the planned regimen of 100 mg/m 2 every 3 weeks as indicated by a median relative dose intensity of 0.98 (range 0.59-1.01).
These results compare well with the 2 previous EORTC Clinical Screening Group phase II studies [11, 12] of docetaxel as first-line chemotherapy, which had similar inclusion criteria to those used in the present study (Table 3 ). The overall response rate was almost identical to that achieved in the other study of full-dose docetaxel [11] (67.6% vs. 67.7%) and higher than that achieved with a lower dose of docetaxel (75 mg/m 2 , 51.6%) [12] , although the latter result is still considered an acceptable overall response rate. Comparing the results of the present study of docetaxel 100 mg/m 2 with the lower-dose study [12] in subgroups of patients with the poorest prognostic factors, response rates were, respectively, 83% and 20% in patients with more than 2 sites of metastatic disease, and 77% and 44% in those with liver metastases. However, because of the small number of patients involved in these analyses, it is not possible to draw firm conclusions regarding the differential effects of the 2 doses in these subgroups.
Most adverse events observed during docetaxel administration were acceptable and easy to manage. Alopecia was almost univeral, and neurosensory effects were confined to mild paraesthesiae and reduction in deep tendon reflexes. Although a large number of patients developed grade 4 neutropenia, this was generally, short-lived, lasting no more than 7 days in 93% of cycles, and febrile neutropenia occurred in only 5 patients (13.5%; 2.5% of cycles). No cumulative haematological suppression was noted, and no cardiotoxicity occurred. Despite routine administration of a 1-day prophylaxis regimen of corticosteroids and H x -and H 2 -receptor antagonists, some mild hypersensitivity reactions occurred, but these were easily managed and did not prevent the affected patients from receiving further cycles. The 1-day prophylaxis regimen was less successful against the development of fluid retention, which led to the eventual discontinuation of 16 patients.
The incidence and onset of fluid retention in the 3 consecutive EORTC Clinical Screening Group trials are compared in Table 4 . It has been suggested that oedema during repeated docetaxel administration may be due to exacerbation of permeability disturbances in the endothelium originally caused by inflammation, and that a regimen containing corticosteroids and antihistamines is useful for its prophylaxis [26] . The results of our present study show that a 1-day regimen of corticosteroid/antihistamine premedication is insufficient for this purpose. More recently, however, it has been demonstrated that a longer duration of oral corticosteroid administration is effective in reducing the incidence of fluid retention (from 61% [n = 118] to 42.9% [n = 63] of patients) and significantly reduces the rate of discontinuation of docetaxel chemotherapy (21% vs. 1.6%; p < 0.001) [13] . A 5-day course of oral dexamethasone 8 mg twice daily, starting the day before docetaxel infusion, has been shown to delay the median onset time of fluid retention from course 3 of docetaxel in non-premedicated patients to course 8 in those who were premedicated [27] . The optimum premedication regimen remains to be defined, and studies with 3-day corticosteroid-based premedication are ongoing.
In conclusion, docetaxel showed a high degree of activity when used as first-line chemotherapy for advanced breast cancer. Particularly good responses were obtained in patients with visceral metastases and in those with 3 or more organs involved. The safety profile was manageable and acceptable: most adverse events were well tolerated and haematological suppression was short-lived.
